Dr. Nagourney's Blog

Email-box.png

Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

Two Lung Cancer Trials Fall Short but Still Hope for HSP90 Inhibitors
By Robert A. Nagourney, MD
Two related clinical trials were reported in the last several months describing the use of heat shock protein 90 (HSP90) inhibitors in lung cancer. Both trials fell short of their pre-specified endpoints casting a pall upon these drugs....
Garlic – The Common Man’s Cure All
By Robert A. Nagourney, MD
A recent study published in the Journal of Cancer Prevention Research by investigators in China compared the outcome of...
Functional Profiling Identifies Accurate Genomic Findings
By Robert A. Nagourney, MD
The 2013 American Society of Clinical Oncology annual meeting, held May 31 – June 1, in Chicago, afforded the opportunity to...
Cure the Curable, Treat the Treatable and Avoid Futile Care
By Robert A. Nagourney, MD
During my interview with Jeff Michaels on the March 28, 5:00 P.M. Fox News, we explored the themes of my current book,...
A Tale of Two Trials - AML & Stage 3 Non Small Cell Lung Cancer
By Robert A. Nagourney, MD
As I read through the November 10 issue of the Journal of Clinical Oncology there were two very different but highly...
November is Lung Cancer Awareness Month
By Robert A. Nagourney, MD
With November designated as Lung Cancer awareness month we have the opportunity to focus national attention on this disease,...
Systems Biology Comes of Age: Metastatic Lung Cancer in the Crosshairs
By Robert A. Nagourney, MD
Cancer therapists have long sought mechanisms to match patients to available therapies. Current fashion revolves around DNA...

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.